AMGEN INC (NASDAQ: AMGN)

AMGEN INC

NASDAQ: AMGN (Amgen Inc.)

Last update: 3 days ago, 7:15AM

265.95

-0.55 (-0.21%)

Add to watchlist

Previous Close	266.50
Open	265.46
Volume	4,664,965
Avg. Volume (3M)	3,007,776
Market Cap	142,956,904,448

Price / Earnings (TTM)	34.01
Price / Earnings (Forward)	13.11
Price / Sales	4.49
Price / Book	19.33

52 Weeks Range	257.80 (-3%) — 346.85 (30%)
Earnings Date	4 Feb 2025 - 10 Feb 2025
TTM Dividend Yield	3.38%

Market Trend

		Short Term	Medium Term
Industry	Drug Manufacturers - General (US)	Bullish	Bullish
	Drug Manufacturers - General (Global)	Bullish	Bullish
Stock	Amgen Inc.	Bullish	Bullish

AIStockmoo Score

1.1

Analyst Consensus	3.5
Insider Activity	-1.5
Price Volatility	3.5
Technical Moving Averages	2.5
Technical Oscillators	-2.5
Average	1.10

Similar Stocks

Stock	Market Cap	DY	P/E (TTM)	P/B
AMGN	143 B	3.38%	34.01	19.33
GILD	113 B	3.40%	1,005.44	6.21
AZN	240 B	1.93%	37.45	5.19
SNY	120 B	8.54%	25.24	1.55
GRFS	6 B	-	32.20	0.830
BIIB	23 B	-	14.35	1.31

Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brings several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
Sector	Healthcare
Industry	Drug Manufacturers - General
Investment Style	Large Value
% Held by Insiders	0.21%
% Held by Institutions	81.08%

52 Weeks Range	257.80 (-3%) — 346.85 (30%)
Price Target Range	215.00 (-19%) — 405.00 (52%)
High	405.00 (Cantor Fitzgerald, 52.28%)	Buy
Median	333.00 (25.21%)
Low	215.00 (Baird, -19.16%)	Sell
Average	332.55 (25.04%)
Total	5 Buy, 4 Hold, 2 Sell
Avg. Price @ Call	307.58

Firm	Date	Target Price	Call	Price @ Call
B of A Securities	10 Dec 2024	256.00 (-3.74%)	Sell	275.75
RBC Capital	27 Nov 2024	330.00 (24.08%)	Buy	280.07
RBC Capital	26 Sep 2024	362.00 (36.12%)	Buy	319.10
Citigroup	14 Nov 2024	335.00 (25.96%)	Hold	295.93
Jefferies	12 Nov 2024	380.00 (42.88%)	Buy	298.84
UBS	31 Oct 2024	326.00 (22.58%)	Hold	320.16
Cantor Fitzgerald	22 Oct 2024	405.00 (52.28%)	Buy	319.66
Cantor Fitzgerald	27 Sep 2024	405.00 (52.28%)	Buy	322.67
TD Cowen	21 Oct 2024	383.00 (44.01%)	Buy	316.74
Bernstein	17 Oct 2024	380.00 (42.88%)	Buy	321.33
Truist Securities	14 Oct 2024	333.00 (25.21%)	Hold	324.62
Barclays	07 Oct 2024	315.00 (18.44%)	Hold	317.45
Baird	25 Sep 2024	215.00 (-19.16%)	Sell	312.86
Show more

No data within this time range.

Date	Type	Details
10 Dec 2024	Announcement	AMGEN ANNOUNCES 2025 FIRST QUARTER DIVIDEND
07 Dec 2024	Announcement	BLINCYTO® (BLINATUMOMAB) ADDED TO CHEMOTHERAPY SIGNIFICANTLY IMPROVES SURVIVAL IN NEWLY DIAGNOSED PEDIATRIC PATIENTS WITH B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL)
05 Dec 2024	Announcement	AMGEN ANNOUNCES $1 BILLION MANUFACTURING EXPANSION IN NORTH CAROLINA
02 Dec 2024	Announcement	AMGEN TO PRESENT AT CITI'S 2024 GLOBAL HEALTHCARE CONFERENCE
29 Nov 2024	Announcement	AMGEN TO PRESENT AT THE 7th ANNUAL EVERCORE HEALTHCONx CONFERENCE
26 Nov 2024	Announcement	AMGEN ANNOUNCES ROBUST WEIGHT LOSS WITH MARITIDE IN PEOPLE LIVING WITH OBESITY OR OVERWEIGHT AT 52 WEEKS IN A PHASE 2 STUDY
26 Nov 2024	Announcement	AMGEN TO HOST WEBCAST TO DISCUSS MARITIDE PHASE 2 RESULTS AND PROGRESS ON DEVELOPMENT PROGRAM
26 Nov 2024	CNBC	Amgen says obesity drug caused up to 20% weight loss after a year, with no plateau
20 Nov 2024	Announcement	AMGEN ANNOUNCES SENIOR EXECUTIVE RESEARCH APPOINTMENT
14 Nov 2024	Announcement	AMGEN PRESENTS NEW DATA ACROSS RARE INFLAMMATORY DISEASES AT ACR 2024
13 Nov 2024	CNBC	Amgen says no concerns around weight loss drug’s bone density data after stock falls
13 Nov 2024	Announcement	AMGEN PROVIDES STATEMENT ON MARITIDE PHASE 1 DATA
13 Nov 2024	Announcement	MOORE LAW ENCOURAGES AMGEN INC. INVESTORS TO CONTACT LAW FIRM
08 Nov 2024	Announcement	AMGEN TO PRESENT AT THE 2024 UBS GLOBAL HEALTHCARE CONFERENCE
08 Nov 2024	Announcement	TEZSPIRE MET BOTH CO-PRIMARY ENDPOINTS IN PHASE 3 TRIAL FOR CHRONIC RHINOSINUSITIS WITH NASAL POLYPS
30 Oct 2024	Announcement	AMGEN REPORTS THIRD QUARTER 2024 FINANCIAL RESULTS
25 Oct 2024	Announcement	AMGEN ANNOUNCES 2024 FOURTH QUARTER DIVIDEND
24 Oct 2024	Announcement	AMGEN ANNOUNCES WEBCAST OF 2024 THIRD QUARTER FINANCIAL RESULTS
15 Oct 2024	Announcement	AMGEN PRESENTS POSITIVE PHASE 3 DATA FOR UPLIZNA® (INEBILIZUMAB-CDON) IN GENERALIZED MYASTHENIA GRAVIS (GMG) AT AANEM 2024
02 Oct 2024	Announcement	Moore Law, PLLC Encourages Amgen, Inc. Investors to Contact Law Firm
01 Oct 2024	Announcement	LA LA ANTHONY PARTNERS WITH AMGEN TO SHARE CANDID, BEHIND-THE-SCENES LOOK AT HOW PLAQUE PSORIASIS AFFECTS HER LIFE
24 Sep 2024	Announcement	TEPEZZA® (TEPROTUMUMAB) RECEIVES APPROVAL IN JAPAN FOR THE TREATMENT OF ACTIVE THYROID EYE DISEASE
23 Sep 2024	Announcement	AMGEN TO HOST CONFERENCE CALL TO DISCUSS NEW TOPLINE DATA IN INFLAMMATION AND RARE DISEASE
Show more

TTM Dividend Yield	3.38%
5Y Average Dividend Yield	2.85%
Payout Ratio	113.41%
Expected Next Dividend Payment	Jun 2025

Ex Date	Announcement Date	Payment Date	Details
14 Feb 2025	10 Dec 2024	07 Mar 2025	2.38 Cash
18 Nov 2024	25 Oct 2024	09 Dec 2024	2.25 Cash
16 Aug 2024	02 Aug 2024	06 Sep 2024	2.25 Cash
16 May 2024	06 Mar 2024	07 Jun 2024	2.25 Cash
15 Feb 2024	12 Dec 2023	07 Mar 2024	2.25 Cash
16 Nov 2023	24 Oct 2023	08 Dec 2023	2.13 Cash
17 Aug 2023	01 Aug 2023	08 Sep 2023	2.13 Cash
17 May 2023	07 Mar 2023	08 Jun 2023	2.13 Cash
14 Feb 2023	12 Dec 2022	08 Mar 2023	2.13 Cash
16 Nov 2022	28 Oct 2022	08 Dec 2022	1.94 Cash
17 Aug 2022	03 Aug 2022	08 Sep 2022	1.94 Cash
16 May 2022	02 Mar 2022	08 Jun 2022	1.94 Cash
14 Feb 2022	03 Dec 2021	08 Mar 2022	1.94 Cash
15 Nov 2021	21 Oct 2021	08 Dec 2021	1.76 Cash
16 Aug 2021	30 Jul 2021	08 Sep 2021	1.76 Cash
14 May 2021	03 Mar 2021	08 Jun 2021	1.76 Cash
11 Feb 2021	16 Dec 2020	08 Mar 2021	1.76 Cash
13 Nov 2020	21 Oct 2020	08 Dec 2020	1.6 Cash
14 Aug 2020	23 Jul 2020	08 Sep 2020	1.6 Cash
15 May 2020	04 Mar 2020	08 Jun 2020	1.6 Cash
13 Feb 2020	11 Dec 2019	06 Mar 2020	1.6 Cash
14 Nov 2019	22 Oct 2019	06 Dec 2019	1.45 Cash
14 Aug 2019	02 Aug 2019	06 Sep 2019	1.45 Cash
16 May 2019	07 Mar 2019	07 Jun 2019	1.45 Cash
14 Feb 2019	07 Dec 2018	08 Mar 2019	1.45 Cash
15 Nov 2018	23 Oct 2018	07 Dec 2018	1.32 Cash
16 Aug 2018	31 Jul 2018	07 Sep 2018	1.32 Cash
16 May 2018	07 Mar 2018	08 Jun 2018	1.32 Cash
14 Feb 2018	12 Dec 2017	08 Mar 2018	1.32 Cash
16 Nov 2017	24 Oct 2017	08 Dec 2017	1.15 Cash
15 Aug 2017	28 Jul 2017	08 Sep 2017	1.15 Cash
15 May 2017	07 Mar 2017	08 Jun 2017	1.15 Cash
13 Feb 2017	20 Dec 2016	08 Mar 2017	1.15 Cash
14 Nov 2016	14 Oct 2016	08 Dec 2016	1 Cash
15 Aug 2016	22 Jul 2016	08 Sep 2016	1 Cash
13 May 2016	02 Mar 2016	08 Jun 2016	1 Cash
11 Feb 2016	15 Dec 2015	08 Mar 2016	1 Cash
12 Nov 2015	14 Oct 2015	07 Dec 2015	0.79 Cash
13 Aug 2015	28 Jul 2015	08 Sep 2015	0.79 Cash
12 May 2015	04 Mar 2015	05 Jun 2015	0.79 Cash
10 Feb 2015	17 Dec 2014	06 Mar 2015	0.79 Cash
10 Nov 2014	17 Oct 2014	05 Dec 2014	0.61 Cash
12 Aug 2014	25 Jul 2014	05 Sep 2014	0.61 Cash
13 May 2014	05 Mar 2014	06 Jun 2014	0.61 Cash
11 Feb 2014	13 Dec 2013	07 Mar 2014	0.61 Cash
12 Nov 2013	16 Oct 2013	06 Dec 2013	0.47 Cash
14 Aug 2013	26 Jul 2013	06 Sep 2013	0.47 Cash
14 May 2013	06 Mar 2013	07 Jun 2013	0.47 Cash
11 Feb 2013	13 Dec 2012	07 Mar 2013	0.47 Cash
Show more

Annual Dividend Yield

Year	Annual Dividend ($)	Frequency/Year	Yield %
2024	9.00	4	3.38
2023	8.52	4	2.96
2022	7.76	4	2.96
2021	7.04	4	3.13
2020	6.40	4	2.78
2019	5.80	4	2.41
2018	5.28	4	2.71
2017	4.60	4	2.65
2016	4.00	4	2.74
2015	3.16	4	1.95
2014	2.44	4	1.53
2013	1.88	4	1.65
Show more

The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.

Portfolio

AI Template

Your price alert

Entry Price (EP)

Take Profit 1 (TP1)

Take Profit 2 (TP2)

Stop Loss (SL)

Realized Profit	-
Unrealized Profit	-
Dividend Received 2024	-
Total Profit	-
Avg. Return	-
Quantity (Buy)	-
Avg. Price (Buy)	-
Quantity (Sold)	-
Avg. Price (Sold)	-

No stocks matching your criteria

Profit Margin	13.00%
Operating Margin (TTM)	24.16%
Diluted EPS (TTM)	7.82
Quarterly Revenue Growth (YOY)	23.20%
Quarterly Earnings Growth (YOY)	63.60%

Total Debt/Equity (MRQ)	802.42%
Current Ratio (MRQ)	1.32
Operating Cash Flow (TTM)	7.26 B
Levered Free Cash Flow (TTM)	4.57 B

Return on Assets (TTM)	4.60%
Return on Equity (TTM)	55.72%

Margin of Safety (EP)
Partial Profit (TP1)
Target Profit (TP2)
Maximum Loss (SL)